Tuesday, October 19, 2010
2010 ACCP Annual Meeting
Austin, TX

ORIGINAL RESEARCH

Ambulatory Care

Andrew Smith, Pharm.D., Jennifer N. Clements, Pharm.D., Daniel S. Longyhore, Pharm.D., BPS, Lea DelaPena, Pharm.D., Beth Bryles Phillips, Pharm.D., Marissa Quinones, Pharm.D., Tiffany C. Rodgers, Pharm.D.; (1)UMKC School of Pharmacy, Kansas City, MO; (2)Bernard J. Dunn School of Pharmacy, Shenandoah University, Winchester, VA; (3)Wilkes University, Wilkes Barre, PA; (4)Midwestern University, Downers Grove, IL; (5)University of Georgia, Athens, GA; (6)Parkland, Dallas, TX; (7)Oklahoma City VA Medical Center, Oklahoma City, OK

Kelly M. Summers, Pharm.D., Rachel A. Boyer, Pharm.D., Patricia Uber, Pharm.D., Mandeeep Mehra, M.D.; (1)U.S. Food and Drug Administration, Silver Spring, MD; (2)CVS, Baltimore, MD; (3)University of Maryland School of Medicine, Baltimore, MD


11. Comparison of Health Spending Resources and Therapeutic Outcomes of a Pharmacist-Managed Anticoagulation Service Compared to Usual Medical Care.
Deanne L. Hall, Pharm.D., Julianne Buchanan, M.S., Bethany E. Helms, Pharm.D., Matthew W. Eberts, Pharm.D., MBA, Yushu Liu, Ph.D., Donald Yoder, B.S., Pamela Peele, Ph.D., Chronis Manolis, RPh, Scott M. Mark, Pharm.D., M.S., Anne B. Docimo, M.D., MBA; (1)University of Pittsburgh School of Pharmacy/University of Pittsburgh Medical Center, Pittsburgh, PA; (2)UPMC Health Plan, Pittsburgh, PA; (3)University of Pittsburgh Medical Center, Pittsburgh, PA

Joseph P. Vande Griend, Pharm.D., Robert B. McQueen, M.A., Sunny A. Linnebur, Pharm.D., FCCP, Sheryl F. Vondracek, Pharm.D., FCCP; University of Colorado School of Pharmacy, Aurora, CO

Jessica E. Wilhoite, Pharm.D., Alison M. Walton, Pharm.D., Karrie A. Morrical-Kline, Pharm.D.; St. Vincent Joshua Max Simon Primary Care Center, Indianapolis, IN

Kelly A. Cochran, Pharm.D., Jeffrey R. Bishop, Pharm.D., M.S., Larisa H. Cavallari, Pharm.D., Nancy L. Shapiro, Pharm.D.; University of Illinois at Chicago College of Pharmacy, Chicago, IL

15. Seasonal Variation in Venous Thromboembolism Incidence: The Influence of Specific Risk Factors in Ambulatory Patients.
Holly H. Chiu, Pharm.D., Jennifer L. Clemente, Pharm.D.; Harper University Hospital, Detroit, MI

16. Outcomes of a Pharmacist-Cardiologist Collaborative Care Model for Hypertension Management in Patients with Cardiovascular Disease.
Sherry V. Laguardia, Pharm.D., Brian K. Irons, Pharm.D., Gary E. Meyerrose, M.D., Kavita Dalal, Pharm.D., Charles F. Seifert, Pharm.D.; (1)Texas Tech University Health Sciences Center School of Pharmacy, Lubbock, TX; (2)Texas Tech University Health Sciences Center School of Medicine, Lubbock, TX; (3)Texas Tech University Health Sciences Center School of Pharmacy, Dallas, TX

17. Effect of Pharmacy Student Interventions in a Family Medicine Setting.
Regina Ginzburg, Pharm.D., Wendy B. Barr, M.D., MPH, MSCE; (1)St. John’s University, Queens, NY; (2)Beth Israel Residency in Urban Family Practice, New York, NY

18. Vitamin K Supplementation for Anticoagulation Control: Do Some Patients Respond Better than Others?
Jennifer L. Clemente, Pharm.D., Peter Whittaker, Ph.D.; (1)Harper University Hospital, Detroit, MI; (2)Wayne State University School of Medicine, Cardiovascular Research Institute and Department of Emergency Medicine, Detroit, MI

Caroline L. Pitney, Pharm.D., Amy M. Drew, Pharm.D., BCPS; St. Louis College of Pharmacy and St. John’s Mercy Medical Center, St. Louis, MO

21. Effect of Daily Vitamin D Supplementation on Hemoglobin A1c in Patients with Uncontrolled Type 2 Diabetes Mellitus.
Mate M. Soric, Pharm.D.,1 Elizabeth Renner, Pharm.D.,1 Steven R. Smith, M.S., RPh,1 Stephen Thomas, Pharm.D.,2 BCPS; (1)The Toledo Hospital Family Medicine Residency, Toledo, OH; (2)Flower Hospital Family Medicine Residency, Sylvania, OH

22. Implications on Vaccine Compliance Rates with the Implementation of a Pharmacist-Driven Vaccination Protocol: Phase 1.
Jamie M. Pitlick, Pharm.D.,1 Abigail M. Yancey, Pharm.D.,2 Alicia B. Forinash, Pharm.D.,1 Thomas Myles, M.D.;1 (1)St. Louis College of Pharmacy, St. Louis, MO; (2)St. Louis College of Pharmacy, St. Louis, MO; (3)St. Louis University, St. Louis, MO

23. Performance of Internal Medicine and Obstetrics and Gynecology Residents on a Case-Based Vaccine Quiz.
Alicia B. Forinash, Pharm.D., BCPS,1 Jamie M. Pitlick, Pharm.D., BCPS,1 Abigail M. Yancey, Pharm.D., BCPS,1 Thomas Myles, M.D., BCPS; (1)St. Louis College of Pharmacy, St. Louis, MO; (2)University of Pittsburgh School of Pharmacy, Pittsburgh, PA; (3)University of Pittsburgh School of Pharmacy/University of Pittsburgh Medical Center, Pittsburgh, PA

24. A Description of Medication Discrepancies Found After Hospital Discharge of Primary Care Patients.
Shara Elrod, Pharm.D.,1 Kim Coley, Pharm.D.,2 Melissa Saul, MSc,1 John Donohoo, RPh,1 Gary Fischer, M.D.,1 Wishwa N. Kapoor, M.D., MPH,1 Deanne L. Hall, Pharm.D.,1 (1)University of Pittsburgh Medical Center, Pittsburgh, PA; (2)University of Pittsburgh School of Pharmacy, Pittsburgh, PA; (3)University of Pittsburgh School of Pharmacy/University of Pittsburgh Medical Center, Pittsburgh, PA

25. An Evaluation of Patients with Type 2 Diabetes Followed by a Pharmaceutical Care Clinic.
Cari Cristiani, Pharm.D., BCPS, Prathima Reddy, Pharm.D., Jun-Yen Yeh, Ph.D., Lisa Potts, Pharm.D., BCPS; Cleveland Clinic, Cleveland, OH

Endocrinology

90E. Initial Treatment with Metformin + Colesevelam Provides Greater Glycemic Control than Metformin Alone in Hispanic Patients with Type 2 Diabetes Mellitus.
Eric Hernandez-Triana, M.D.,1 W. Timothy Garvey, M.D.,2 Ronald B. Goldberg, M.D.,3 Yehuda Handelsman, M.D.,4 Vivian A. Fonseca, M.D.,5 Michael R. Jones, Ph.D.,6 Stacey L. Abby, Pharm.D.,6 Yu-Ling Lai, RNC, MSN,7 Xiaoqing Jin, Ph.D.,8 Soamnauth Misir, Pharm.D.,7 Sukumar Nagendran, M.D.,7 Stacey L. Abby, Pharm.D.,7; (1)The University of Pittsburgh School of Pharmacy, Jackson, MS; (2)University of Mississippi School of Pharmacy, Jackson, MS; (3)Mississippi Baptist Medical Center, Jackson, MS

92. Effect of Statin Lipophilicity and Dose on Adiponectin Concentrations: A Systematic Review and Meta-analysis.
Daniel M. Riche, Pharm.D., BCPS, CDE,1 S. Travis King, Pharm.D.,2 Krista D. Riche, Pharm.D., BCPS; (1)The University of Mississippi School of Pharmacy, Jackson, MS; (2)Metabolic Institute of America, Tarzana, CA; (3)Mississippi Baptist Medical Center, Jackson, MS

Hematology/Anticoagulation

103. Comparison of Unfractionated Heparin versus Enoxaparin for Venous Thromboembolism Prophylaxis in the Very Elderly.
Luigi Brunetti, Pharm.D., CGP,1 Paul Auriemma, Pharm.D., Candidate,1 Fatema Dhanalwala, RPh; (1)Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ; (2)Somerset Medical Center, Somerville, NJ

Hematology/Anticoagulation

104. Benchmarking the Use of Iron Dextran Infusions in Non-CKD and Non-cancer Patients in an Academic Teaching Hospital.
105. Evaluation of a Direct Thrombin Inhibitor Titration Protocol in Patients with Heparin-Induced Thrombocytopenia (HIT).

Allison M. Mann, Pharm.D., Toby C. Trujillo, Pharm.D., BCPS, Kathryn L. Hassell, M.D., Tyree H. Kiser, Pharm.D., BCPS; (1)University of Colorado Hospital, Aurora, CO; (2)University of Colorado School of Pharmacy, Aurora, CO; (3)University of Colorado School of Medicine, Aurora, CO

106E. Monitoring and Treatment Among Patients with Transfusional Iron Overload: Preliminary Findings from an Electronic Medical Records Review Study at H. Lee Moffitt Cancer Center and Research Institute.

Leslie A. Ray, Pharm.D., Gene A. Wetzstein, Pharm.D., BCOP, Caroline Korves, ScD, Si-Tien Wang, M.S., Bentley Clinton, B.A., Robert Wei, B.A., Mitra Corral, M.S., MPH, Mei Sheng Duh, MPH, ScD; (1)H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; (2)Analysis Group, Inc., Boston, MA; (3)Novartis Pharmaceuticals Corporation, East Hanover, NJ

107. Initial Evaluation for Gastrointestinal Prophylaxis in Patients Receiving Concomitant Warfarin and Antiplatelet Therapy at Jesse Brown VA Medical Center.

Claresta Bergman, Pharm.D., BCPS, Blair J. Schwartz, Pharm.D.; Jesse Brown VA Medical Center, Chicago, IL

108. Iron Deficiency (ID) and Anemia After Roux-en-Y Gastric Bypass (RYGBP).

Margaret Malone, Ph.D., FCCP, Sharon Alger-Mayer, M.D., Jennifer Lindstrom, M.D., George R. Bailie, Pharm.D.; (1)Albany College of Pharmacy and Health Sciences, Albany, NY; (2)Albany Medical College, Albany, NY

109. Hospital Characteristics and Guidelines Regarding the Management of Heparin-Induced Thrombocytopenia (HIT) in U.S. Hospitals (the HIT-ME study).

Alan S. Multz, M.D.; Nassau University Medical Center, East Meadow, NY

110. PREVENT-HIT: A Randomized, Comparative Trial of Desirudin vs. Argatroban in Suspected HIT.

Steven W. Boyce, M.D., Dennis F. Bandyk, M.D., Lawrence Rice, M.D.; (1)Washington Hospital Center, Washington, DC; (2)University of South Florida, Tampa, FL; (3)Methodist Academic Medicine Associates – Weill Cornell Medical College, Houston, TX

111. Efficacy of Intravenous Heparin Monitoring Using a Heparin Antifactor Xa Assay.

Adrian P. Sykes, Pharm.D., Sarah M. Gaffney, Pharm.D., BCPS, Amy R. Knauss, Pharm.D., BCPS; Northeast Georgia Health System, Gainesville, GA

112E. Superior Oral Anticoagulation Management with Self-testing and Automated Management; an Interim Analysis.

Henry I. Bussey Jr., B.S., Pharm.D., Christopher Frei, Pharm.D., Marie Walker, BBA, Kristin Bussey-Smith, M.D.; (1)The University of Texas at Austin, University of Texas Health Science Center at San Antonio, and Genesis Clinical Research, San Antonio, TX; (2)The University of Texas at Austin and University of Texas Health Science Center at San Antonio, San Antonio, TX; (3)ClotCare and Genesis Advanced Technologies, Inc., San Antonio, TX; (4)Allergy, Asthma, Immunology & Rheumatology Institute, San Antonio, TX

113E. INR Self-testing in Warfarin Anticoagulation Improves Patient Satisfaction and Clinic Efficiency While Reducing Patient Costs.

Henry I. Bussey Jr., B.S., Pharm.D., Nicolas A. Forcade, Pharm.D., Marie Walker, BBA, Christopher Frei, Pharm.D., Kristin Bussey-Smith, M.D., Kelly R. Daniels, Pharm.D., Candidate; (1)University of Texas HSC and Genesis Clinical Research, San Antonio, TX; (2)The University of Texas at Austin and The University of Texas Health Science Center San Antonio, San Antonio, TX; (3)ClotCare and Genesis Advanced Technologies, Inc., San Antonio, TX; (4)The University of Texas at Austin College of Pharmacy and The University of Texas Health Science Center at San Antonio, San Antonio, TX; (5)Allergy, Asthma, Immunology & Rheumatology Institute, San Antonio, TX; (6)The University of Texas at Austin and University of Texas Health Science Center at San Antonio, San Antonio, TX


Maria Pham, Pharm.D., Johanna L. Norman, Pharm.D., Candidate, Kelly C. Rogers, Pharm.D., Shannon W. Finks, Pharm.D., Robert Parker, Pharm.D.; (1)Veterans Affairs Medical Center Memphis, Memphis, TN; (2)University of Tennessee Health Science Center, Memphis, TN; (3)University of Tennessee College of Pharmacy, Memphis, TN


Lucas Gasco, Pharm.D., Jonathan W. Ho, Pharm.D., Vincent W. Li, Pharm.D., Jeffery R. Proctor, Pharm.D., Betty J. Dong, Pharm.D.; (1)Wilford Hall Medical Center, Lackland AFB, TX; (2)CVS Pharmacy, Visalia, CA; (3)VA Hospital, Palo Alto, CA; (4)Safeway Pharmacy, San Francisco, CA; (5)University of California–San Francisco, San Francisco, CA
116E. SHIELD: 48-Week Results of Abacavir/Lamivudine (ABC/3TC) and Raltegravir (RAL) in Antiretroviral-Naive HIV-1-Infected Subjects. Benjamin Young, M.D., Ph.D.,1 Thanes Vanig, M.D.,2 Edwin DeJesus, M.D.,3 Trevor Hawkins, M.D.,4 Marty St. Clair, B.S.,5 Linda H. Yau, Ph.D.,5 Belinda Ha, Ph.D.5; (1)Rocky Mountain CARES/DIDC, Denver, CO; (2)Spectrum Medical Group, Phoenix, AZ; (3)Orlando Immunology Center, Orlando, FL; (4)Southwest Care Clinic, Santa Fe, NM; (5)GlaxoSmithKline, Research Triangle Park, NC

117E. Fosamprenavir/Ritonavir (FPV/r) vs. Efavirenz (EFV) with Abacavir/Lamivudine (ABC/3TC) in Underrepresented, Antiretroviral (ARV)-Naïve, HIV-Infected Subjects (SUPPORT): 24-Week Efficacy, Safety, and Tolerance. Princy N. Kumar, M.D.,1 Edwin DeJesus, M.D.,2 Gregory Huhn, M.D., Gregory Sloan, M.D.,1 Fernando Garcia, M.D.,1 Catherine Small, M.D.,1 Howard Edelstein, M.D.,2 Franco Felizarta, M.D.,8 Ritchie Hao, M.D.,10 Katrina Oie, Ph.D.,10 Lisa L. Ross, M.S.,10 Britt S. Stancil, B.S.,10 Belinda Ha, Ph.D.,10 Keith Pappa, Pharm.D.,10; (1)Georgetown University, Washington, DC; (2)Orlando Immunology Center, Orlando, FL; (3)Ruth M. Rothstein CORE Center, Chicago, IL; (4)Baylor University Medical Center, Dallas, TX; (5)Valley AIDS Council, Harlingen, TX; (6)New York Medical College, Valhalla, NY; (7)Alameda County Medical Center, Oakland, CA; (8)Franco Felizarta, M.D., Bakersfield, CA; (9)Chase Breton Health Services, Inc., Baltimore, MD; (10)GlaxoSmithKline, Research Triangle Park, NC

118. Evaluation of the Incidence and Severity of Vitamin D Deficiency in a Southeastern U.S. HIV-Infected Population. Kelly Hester, Pharm.D., BCPS,1 Brandon Hicks, Pharm.D.2; (1)Auburn University Harrison School of Pharmacy, Auburn, AL; (2)Harrison School of Pharmacy, Auburn University, Auburn, AL

Infectious Diseases

119. Impact of a Pharmacy Practice Resident on an Antimicrobial Stewardship Program During an Elective Learning Experience in Infectious Diseases. Ashley B. Townsend, Pharm.D., Elias B. Chahine, Pharm.D., BCPs, Palm Beach Atlantic University, Lloyd L. Gregory School of Pharmacy, West Palm Beach, FL

120E. High-Dose Vancomycin for Methicillin-Resistant Staphylococcus aureus Ventilator-Associated Pneumonia. Leslie A. Hamilton, Pharm.D.,1 G. Christopher Wood, Pharm.D.,2 Louis J. Magnotti, M.D.,2 Martin A. Croce, M.D.,2 Joseph M. Swanson, Pharm.D.,2 Bradley A. Boucher, Pharm.D.,2 Timothy C. Fabian, M.D.2; (1)Auburn University, Birmingham, AL; (2)University of Tennessee Health Science Center, Memphis, TN

121. Moxidectin Does Not Induce CYP3A4 Activity When Evaluated by Oral Midazolam Pharmacokinetics in Healthy Subjects. Joan Korth-Bradley, Pharm.D., Ph.D.,1 Virginia Parks, BSc (Hons),2 Stephan Chalon, M.D., Ph.D.,2 Ian Gourley, M.D.,1 Kyle Matschke, MAS,1 Sophie Gossart, MSc,2 Lawrence L. Fleckenstein, Pharm.D.3 Frank Wagner, Dr. Med.4; (1)Pfizer Inc., Collegeville, PA; (2)Wyeth Research, París, France; (3)University of Iowa, Iowa City, IA; (4)Charite Research Organisation GmbH, Berlin, Germany

122. Outcomes of Daptomycin (DAP) Treatment in Intensive Care Unit (ICU) Patients (pts) with Gram-positive Bloodstream Infections (GPBSI). Marina B. Rabinovich, Pharm.D., BCPS,1 Prasad Abraham, Pharm.D., BCPS,1 Katherine P. Holloway, Pharm.D., BCPS,2 Hina N. Patel, Pharm.D., BCPS2; (1)Grady Health System, Atlanta, GA; (2)Cubist Pharmaceuticals, Lexington, MA

123. Retrospective Assessment of Vancomycin Dosing Requirements in Pediatric Burn Patients. Stephanie Wead, Pharm.D.,1 Daniel P. Healy, Pharm.D.,1 Roy Saylors, BSPharm,2 Mary T. Rieman, RN, BSN,2 Paula Durkee, B.S.,2 Alice N. Neely, Ph.D.,2 Richard J. Kagan, M.D.2; (1)James Winkle College of Pharmacy, University of Cincinnati, Cincinnati, OH; (2)Shriners Hospitals for Children – Cincinnati, Cincinnati, OH

124. Retrospective Evaluation of Antibiotic Prescribing with Heart Failure. John Smith, Pharm.D.,1 Yasir Tasnif, Pharm.D.,2 Elena Guerra, Pharm.D., Candidate; (1)Valle Baptist Medical Center, Harlingen, TX; (2)University of Texas at Pan American, Edinburg, TX; (3)University of Houston, Houston, TX


126E. Role of CgUPC2 in the Susceptibility of Candida glabrata to Fluconazole. Kelly E. Caudle, Pharm.D., Ph.D.,1 Nathan P. Wiederhold, Pharm.D.,2 Katherine S. Barker, Ph.D.,1 P. David Rogers, Pharm.D., Ph.D.1; (1)The University of Tennessee Health Science Center, Memphis, TN; (2)The University of Texas Health Science Center at San Antonio, San Antonio, TX
128E. Activity of Meropenem and Colistin Alone and in Combination Against Multidrug-Resistant *Acinetobacter baumannii* in a Pharmacokinetic-Pharmacodynamic Model. 
Warunee Srisupha-olarn, Pharm.D., David S. Burgess, Pharm.D., FCCP, University of Texas at Austin College of Pharmacy and University of Texas Health Science Center San Antonio School of Medicine, San Antonio, TX

129E. In Vitro Activity of Carbapenems Alone and in Combination with Amikacin Against KPC-Producing *K. pneumoniae* Isolates. 
David S. Burgess, Pharm.D., FCCP,1 Barbara McKee, MT (ASCP),2 Warunee Srisupha-olarn, Pharm.D.,3 Jennifer Le, Pharm.D., BCPS-ID4; (1)University of Texas at Austin College of Pharmacy and University of Texas Health Science Center School of Medicine, San Antonio, TX; (2)Long Beach Memorial Medical Center, Long Beach, CA; (3)University of Texas Health Science Center, San Antonio, TX; (4)University of California San Diego, Skaggs School of Pharmacy and Pharmaceutical Sciences, La Jolla, CA

Gregory Smallwood, Pharm.D.,1 Tim Barnett, Ph.D.,2 Katie Casper, M.S.,2 Thomas Heffron, M.D.3; (1)PCOM School of Pharmacy, Suwanee, GA; (2)Children’s Healthcare of Atlanta, Atlanta, GA; (3)Emory Healthcare, Atlanta, GA

131E. In Vitro Activity of MK-7655 in Combination with Imipenem (IPM) Against Carbapenem-Resistant Gram-negative Bacteria. 
Elizabeth B. Hirsch, Pharm.D.,1 Kimberly R. Ledesma, B.S.,1 Kai T. Chang, Ph.D.,1 Mary M. Motyl, Ph.D. D(ABMM),2 Vincent H. Tam, Pharm.D.,1; (1)University of Houston, Houston, TX; (2)Merck & Co., Inc., Rahway, NJ

132E. Prospective Validation of a Model to Predict Mortality Following *Pseudomonas aeruginosa* (PA) Bacteremia. 
Elizabeth B. Hirsch, Pharm.D.,1 Jessica M. Cottreau, Pharm.D.,1 Juan P. Caiero, M.D.,1 Michael L. Johnson, Ph.D.,2 Vincent H. Tam, Pharm.D.,2; (1)University of Houston, Houston, TX; (2)St. Luke’s Episcopal Hospital, Houston, TX

133. Tuberculosis Treatment Outcomes: A Retrospective Cohort Analysis of Smoking versus Non-smoking Patients in the State of Penang, Malaysia. 
Juman A. Dujaili, MPharm,1 Syed Azhar Syed Sulaiman, Pharm.D.,1 Ahmed Awaisu, Ph.D.,1 Abdul Razak Muttalif, M.Med.,2 Ali Q. Jaafar, MPharm;1 (1)School of Pharmaceutical Science, Universiti Sains Malaysia, Minden, Malaysia; (2)Department of Respiratory Medicine, Penang Hospital, Jalan Residensi, Malaysia

134. Stability and Compatibility of Candidate Antifungal Lock Solutions of Micafungin. 
P. Brandon Bookstaver, Pharm.D., BCPS (AQ-ID), AAHIVE, Jessica Harris, Pharm.D., Candidate, Mary B. Sides, B.S., M.S., Celeste N. Rudisill, Pharm.D.; South Carolina College of Pharmacy, USC Campus, Columbia, SC

135. Outcomes in Obese Patients on High Doses of Daptomycin (DAP): Experience of Fifteen Institutions in the Southeastern United States. 
P. Brandon Bookstaver, Pharm.D., BCPS (AQ-ID), AAHIVE,1 Christopher M. Bland, Pharm.D., BCPS,2 Carmen Faulkner, Pharm.D., BCPS (AQ-ID),3 Charles E. Hartis, Pharm.D., BCPS,4 Benjamin Britt, Pharm.D.,5 Brianne Dunn, Pharm.D.,6 Celeste N. Rudisill, Pharm.D.,1 Brian Odle, Pharm.D.,1’7 Katie Fulton, Pharm.D.,4’7 Linsey Hocker, Pharm.D.,7; (1)South Carolina College of Pharmacy, USC Campus, Columbia, SC; (2)Dwight D. Eisenhower Army Medical Center, Fort Gordon, GA; (3)Greenville Hospital System University Medical Center, Greenville, SC; (4)Forsyth Medical Center, Winston-Salem, NC; (5)Providence Hospital, Columbia, SC; (6)Medical University of South Carolina, Charleston, SC; (7)Bill Gatton College of Pharmacy, East Tennessee State University, Johnson City, TN; (8)Pitt County Memorial Hospital, Greenville, NC

Christopher A. Giuliano, Pharm.D.,1 Krystal K. Haase, Pharm.D., BCPS,1 Kathleen Hazelwood, Pharm.D.,2 Carlos A. Alvarez, Pharm.D., MSc,3 Nicolas A. Forcade, Pharm.D.,4 Christopher R. Frei, Pharm.D., MSc, BCPS,4 Sara D. Brouse, Pharm.D.,3 Todd Bell, M.D.,1 Roger Bedimo, M.D., M.S.,5 Ronald G. Hall, Pharm.D., BCPS3; (1)Texas Tech University Health Sciences Center, Amarillo, TX; (2)The University of Wyoming School of Pharmacy, Laramie, WY; (3)Texas Tech University Health Sciences Center and the Dallas Veterans Affairs Medical Center, Dallas, TX; (4)The University of Texas at Austin and The University of Texas Health Science Center San Antonio, San Antonio, TX; (5)The University of Texas at Austin and The University of Texas Health Science Center San Antonio, Dallas, TX

137. Is it Time to Change How Outpatient Urinary Tract Infections Are Treated? 
David A. Bookstaver, Pharm.D., Sary O. Beidas, M.D.; Eisenhower Army Medical Center, Fort Gordon, GA

138E. Daptomycin Use in Neutropenic Patients with Documented Gram-positive Infections.
139E. Guideline-Concordant Therapy Is Not Associated with Improved Outcomes in Healthcare-Associated Pneumonia.
Russell T. Attridge, Pharm.D., MSc, BCPS,1 Christopher R. Frei, Pharm.D., MSc, BCPS,2 Marcos I. Restrepo, M.D., MSc,3 Kenneth A. Lawson, Ph.D.,4 Laurajo Ryan, Pharm.D., MSc, BCPS, CDE,2 Eric M. Mortensen, M.D., MSc3; (1)University of the Incarnate Word Feik School of Pharmacy, San Antonio, TX; (2)The University of Texas at Austin and The University of Texas Health Science Center San Antonio, San Antonio, TX; (3)University of Texas Health Science Center, Veterans Evidence-Based Research Dissemination and Implementation Center, and South Texas Veterans Health Care System, San Antonio, TX; (4)The University of Texas at Austin, Austin, TX

140E. Safety and Clinical Outcomes of Daptomycin for Staphylococcus aureus Bacteremia in Non-dialysis Patients with Renal Insufficiency.
Pamela A. Moise, Pharm.D.,1 Maria Amodio-Groton, Pharm.D.,1 Mohamad Rashid, M.D.,2 Kenneth C. Lamp, Pharm.D.,1 Holly Hoffman-Roberts, Pharm.D.,1 MinJung Yoon, MPH,1 Ann Hernandez, B.S.,2 Suzanne Schweitzer, BSPharm, MPH,2 Anjay Rastogi, M.D., Ph.D.2; (1)Cubist Pharmaceuticals, Lexington, MA; (2)UCLA Division of Nephrology, Los Angeles, CA

141E. FOCUS 1 and 2: Randomized, Double-blinded, Multicenter Phase 3 Trials of the Efficacy and Safety of Ceftraroline Fosamil vs. Ceftriaxone in Community-Acquired Pneumonia.
Paul Eckburg, M.D.,1 David Friedland, M.D., MBA,1 Jon Lee,1 Lily Llorens, Ph.D.,1 Ian Critchley, Ph.D.,1 Joseph B. Laudano, Pharm.D.,2 Charley Merrill, Ph.D., MBA,2 Dirk Thye, M.D.; (1)Cerexa, Inc.; a wholly owned subsidiary of Forest Laboratories, New York, NY; (2)Forest Research Institute, Jersey City, NJ

Robert T. Adamson, Pharm.D.,1 Shilpa Amara, Pharm.D.,1 Ariel Berger, MPH,2 Kenneth LaPensee, Ph.D., MPH,3 Gerry Oster, Ph.D.; (1)Saint Barnabas Health Care System, South Plainfield, NJ; (2)Policy Analysis Inc., Brookline, MA; (3)Forest Research Institute, Jersey City, NJ

143. Vancomycin: Impact of a Pharmacy Consult Service for Guideline-Based Therapeutic Monitoring.
Jessica T. Clark, Pharm.D., Christy M. Vaughan, Pharm.D., BCPS; Methodist Dallas Medical Center, Dallas, TX

145. Lack of Changes to Vancomycin Based on Microbiologic Culture Data: Possible Intervention for Antibiotic Stewardship Programs.
Euphemia Uhegbu, Pharm.D.,1 Kimberly Halton, Pharm.D.,2 Kristi Kuper, Pharm.D.,3 Kevin W. Garey, Pharm.D.,3 Harminder Sikand, Pharm.D.,1; (1)Scripps Mercy Hospital, San Diego, CA; (2)University of Houston College of Pharmacy, Houston, TX; (3)Cardinal Health Pharmacy Services, Houston, TX

146. Relationship Between Vancomycin Serum Trough Levels and Clinical Outcomes in a Veteran Population with Methicillin-Resistant Staphylococcus aureus Bacteremia.
Kimberly Tamura, Pharm.D., Thi Doan, Pharm.D., Ronald Brown, M.S., RPh; Portland Veterans Affairs Medical Center, Portland, OR

147. Relationship of Microbiological and Virulence Characteristics to Staphyloxanthin (STX) Production in Methicillin-Resistant Staphylococcus aureus (MRSA).
Michael S. North, Pharm.D.,1 Brian Werth, Pharm.D.,1 Jora Sliwinski, Pharm.D., Candidate,1 Paulina Deming, Pharm.D.,2 George Sakoulas, M.D.,2 Renee C. Mercier, Pharm.D.,1; (1)University of New Mexico Health Sciences Center, Albuquerque, NM; (2)Cardinal Health Pharmacy Services, Houston, TX

149E. Development of a Candida glabrata PDR1 Mutation During Itraconazole Therapy for Oropharyngeal Candidiasis.
Philip Graves, M.S.,1 Nathan P. Wiederhold, Pharm.D.,2 Steven Mayen, B.A.,1 Steven D. Westbrook, DMD,1 Deborah K. Berg, BSN,1 William R. Kirkpatrick, M.S.,1 Spencer W. Redding, DDS,1 Thomas F. Patterson, M.D.1; (1)University of Texas Health Science Center at San Antonio, San Antonio, TX; (2)University of Texas at Austin, Austin, TX

Kristi Kuper, Pharm.D.,1 Alisa Goetz, Pharm.D.,1 Amy Jackson, CPhT,1 Kevin W. Garey, Pharm.D., M.S.2; (1)Cardinal Health Pharmacy Solutions, Houston, TX; (2)University of Houston-College of Pharmacy, Houston, TX

Nathan P. Wiederhold, Pharm.D.,1 Christopher R. Thornton, Ph.D.,2 Laura K. Najvar, B.S.,3 Rosie
152. Steady-state Pharmacokinetics and Pharmacodynamics of Cefepime, Administered by Prolonged Infusion, in Hospitalized Patients.
S. Christian Cheatham, Pharm.D., Katherine M. Shea, Pharm.D., Melissa L. Humphrey, Pharm.D., Candidate, Megan R. Fleming, Pharm.D., Daniel P. Healy, Pharm.D., Matthew W. Smith, Pharm.D., Kevin M. Sowinski, Pharm.D., Michael Kays, Pharm.D.; (1)St. Francis Hospitals and Health Centers, Beech Grove, IN; (2)University Medical Center at Brackenridge, Austin, TX; (3)Purdue University School of Pharmacy, West Lafayette, IN; (4)James Winkle College of Pharmacy, University of Cincinnati, Cincinnati, OH; (5)Infectious Diseases of Indiana, Indianapolis, IN; (6)Clarian Health Partners, Inc., Methodist Hospital, Indianapolis, IN; (7)Purdue University School of Pharmacy, Indianapolis, IN

154. Relationship Between Higher Vancomycin Trough Levels and the Incidence of Nephrotoxicity.
Christine J. Yu, Pharm.D., Howard K. Umemoto, Pharm.D., Linh B. Van, Pharm.D., BCPS (AQ-ID); (1)Kaiser Permanente Oakland Medical Center, Oakland, CA; (2)Kaiser Permanente Riverside Medical Center, Riverside, CA

Kurt R. Winkler, Pharm.D., MHA, BCPS; Donna R. Burgess, B.S., Tony Dasher, Pharm.D., David S. Burgess, Pharm.D., FCCP; (1)Methodist Hospital Department of Pharmacy, San Antonio, TX; (2)University of Texas at Austin College of Pharmacy and University of Texas Health Science Center School of Medicine, San Antonio, TX

156. Effect of the Infusion Time Duration on the Pharmacodynamics of Piperacillin/Tazobactam and Cefepime.
Michael B. Kays, Pharm.D., S. Christian Cheatham, Pharm.D., Katherine M. Shea, Pharm.D., Melissa L. Humphrey, Pharm.D., Candidate, Megan R. Fleming, Pharm.D., Daniel P. Healy, Pharm.D., David W. Smith, Pharm.D., Matthew F. Wack, M.D., Kevin M. Sowinski, Pharm.D.; (1)Purdue University School of Pharmacy, Indianapolis, IN; (2)St. Francis Hospitals and Health Centers, Beech Grove, IN; (3)University Medical Center at Brackenridge, Austin, TX; (4)Purdue University School of Pharmacy, West Lafayette, IN; (5)James Winkle College of Pharmacy, University of Cincinnati, Cincinnati, OH; (6)Clarian Health Partners, Inc., Methodist Hospital, Indianapolis, IN; (7)Infectious Diseases of Indiana, Indianapolis, IN

Mark A. Stacy, M.D.,1 François Laliberté, M.A.,2 Amit S. Kulkarni, Ph.D.,3 Monique Somogyi, M.D.,3 Francis Vekeman, M.A.,2 Mei-Sheng Duh, MPH, ScD,2 Patrick Lefebvre, M.A.2; (1)Duke University Medical Center, Durham, NC; (2)Groupe d’analyse, Ltée, Montréal, QC, Canada; (3)Novartis Pharmaceuticals Corporation, East Hanover, NJ; (4)Analysis Group, Inc., Boston, MA


M. Scot Mason, Pharm.D.,1 Anthony B. Russell, Ph.D.,1 Karen Wisont, M.S.,1 Stephen Stemkowski, MHA, Ph.D.,2 Bernadette H. Johnson, B.S., MBA;2 George M. Rodgers, M.D., Ph.D.;2 (1)ZymoGenetics, Inc., Seattle, WA; (2)Premier, Inc., Charlotte, NC; (3)University of Utah Health Sciences Center, Salt Lake City, UT

188. Health Outcomes Experienced by Daptomycin-Treated Patients with MRSA Infections.

Debra A. Goff, Pharm.D., FCCP,1 Peggy S. McKinnon, Pharm.D.,2 Amanda J. Boening, Pharm.D.,2 Thomas P. Lodise, Pharm.D.; (1)The Ohio State University Medical Center, Columbus, OH; (2)Cubist Pharmaceuticals, Lexington, MA; (3)Albany College of Pharmacy, Albany, NY

Pharmacoepidemiology

189. Impact of Generic Substitution of Lamotrigine in a State Medicaid Population: A Retrospective Crossover Cohort Study.

Daniel Hartung, Pharm.D., MPH,1 Leanne Svboda, Pharm.D.,2 Luke Middleton, B.S.,1 Jessina C. McGregor, Ph.D.;1 (1)Oregon State University, Portland, OR; (2)Oregon Health & Science University, Portland, OR; (3)Oregon State University/Oregon Health & Science University College of Pharmacy, Portland, OR


Pamela L. Smithburger, Pharm.D.,1 Leanne Svoboda, Pharm.D.,2 Luke Middleton, B.S.,1 Jessina C. McGregor, Ph.D.;1 (1)Oregon State University, Portland, OR; (2)Oregon Health & Science University, Portland, OR; (3)Oregon State University/Oregon Health & Science University College of Pharmacy, Portland, OR

191. Medication Adherence in Medicaid Patients with Dyslipidemia.

Michael W. Daly, Pharm.D.,1 Terry Seaton, Pharm.D.,1 Nathan Moore, B.S.,2 Frances Wang, B.S.,2 Adam Ralko, M.D.;2 Thomas Bailey, M.D.;2 St. Louis College of Pharmacy, St. Louis, MO; (2)Washington University, St. Louis, MO

Pharmacogenomics/Pharmacogenetics

192. Genetic Predictors of Valproic Acid Response in Patients with Bipolar Disorder.

Kelly C. Lee, Pharm.D., BCPP,1 Tanya Shekhtman, B.S.,2 Rebecca McKinney, B.S.,2 John R. Kelsoe, M.D.;2 (1)University of California, San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences, La Jolla, CA; (2)University of California, San Diego Department of Psychiatry, La Jolla, CA


Susanne B. Haga, Ph.D.,1 Julianne O’Daniel, M.S.;1 Genevieve M. Tindall, B.A.;1 Robert Agans, Ph.D.;2 (1)Institute for Genome Sciences & Policy, Duke University, Durham, NC; (2)Survey Research Unit, University of North Carolina, Chapel Hill, NC


Diana X. Cao, Pharm.D., Jaekyu Shin, Pharm.D.; University of California–San Francisco, San Francisco, CA

Pharmacokinetics/Pharmacodynamics/Drug Metabolism/Drug Delivery


Myrna Y. Munar, Pharm.D.,1 Ganesh Cherala, Ph.D.,1 Amira Al-Uzri, M.D.;2 (1)Department of Pharmacy Practice, Oregon State University/Oregon Health & Science University College of Pharmacy, Portland, OR; (2)Department of Pediatrics, Division of Pediatric Kidney Services and Hypertension, Oregon Health & Science University, Portland, OR


Eric Poulin, BScPharm,1 Erica D. Greanya, BScPharm, Pharm.D., ACPR,1 Nilufar Partovi, BScPharm, Pharm.D.,2 R. Jean Shapiro, M.D., FRCPC,2 Mai Al-Khatib, BScPharm, MScPharm,4 Mary H.H. Ensom, Pharm.D., FASHP, FCCP, FCSPH, FCAHS;1 (1)Vancouver General Hospital, Vancouver, BC, Canada; (2)University of British Columbia and Vancouver General Hospital, Vancouver, BC, Canada; (3)University of British Columbia, Vancouver General Hospital, Vancouver; (4)University of British Columbia, Vancouver, BC, Canada; (5)University of British Columbia, Children’s & Women’s Health Centre of British Columbia, Vancouver, BC, Canada
Tina H. Denetclaw, Pharm.D., BCPS,1 Bogdan H. Wapniarski, Pharm.D.,2 Douglas T. Steinke, Ph.D.3; (1)University of California at San Francisco School of Pharmacy, San Francisco, CA; (2)Marin General Hospital, Greenbrae, CA; (3)UK HealthCare, Lexington, KY

198. Cyclophosphamide Pharmacokinetics in Glomerulonephritis.
Melanie S. Joy, Pharm.D., Ph.D.,1 Mary La, B.S. (in progress),2 Jinzhao Wang, B.S.,2 Arlene S. Bridges, Ph.D.,2 Yichun Hu, M.S.,2 Susan L. Hogan, MPH, Ph.D.,2 Reginald F. Frye, Pharm.D., Ph.D.,3 Joyce A. Blaisdell, B.S.,4 Joyce A. Goldstein, Ph.D.,4 Mary Anne Dooley, M.D., MPH,2 Kim L.R. Brouwer, Pharm.D., Ph.D.,5 Ronald J. Falk, M.D.2; (1)University of North Carolina, Schools of Medicine and Pharmacy, Chapel Hill, NC; (2)University of North Carolina, School of Medicine, Chapel Hill, NC; (3)College of Pharmacy and Center for Pharmacogenomics, University of Florida, Gainesville, FL; (4)NIH NIEHS, Research Triangle Park, NC; (5)University of North Carolina, School of Pharmacy, Chapel Hill, NC

199. Concentration-Dependent Protein Binding of Tigecycline in Adult Diabetic Patients.
Catharine C. Bulik, Pharm.D., Dora E. Wiskirchen, Pharm.D., Christina A. Sutherland, B.S., Joseph L. Kuti, Pharm.D., David P. Nicolau, Pharm.D., FCCP, FIDSA; Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, CT

Thomas C. Dowling, Pharm.D., Ph.D.,1 Steven L. Allison, Pharm.D.2; (1)University of Maryland, School of Pharmacy, Baltimore, MD; (2)Pitt County Memorial Hospital, Greenville, NC

CLINICAL PHARMACY FORUM

Ambulatory Care

M. Shawn McFarland, Pharm.D., Rebecca Cripps, Pharm.D., Regina Cassidy, Pharm.D., Timothy Morgan, Pharm.D., Wendy Johnson, Pharm.D., Dharapuram Venugopal, M.D.; Veterans Affairs Tennessee Valley Healthcare System, Murfreesboro, TN

224. Assessment of the Monitoring and Follow-up of Patients Prescribed Darbepoetin in a Chronic Kidney Disease Clinic.
Megan M. Bergstrom, Pharm.D., Anthony M. Ishak, Pharm.D., BCPS; Boston Medical Center, Boston, MA

Melissa J. Snider, Pharm.D., BCPS, CLS, Cynthia Carnes, Pharm.D., Ph.D., Janel Grover, MHA, Rich Davis, Ph.D., Steven Kalbfleisch, M.D.; Ohio State University Medical Center, Columbus, OH

226. Glycemic Control and Preventative Care Measures of Indigent Diabetes Patients Within a Pharmacist-Managed Insulin Titration Program vs. Standard Care.
Marissa C. Salvo, Pharm.D.,1 Amie D. Brooks, Pharm.D., BCPS2; (1)University of Connecticut – School of Pharmacy, Storrs, CT; (2)St. Louis College of Pharmacy, St. Louis, MO

Autumn S. Tami, Pharm.D., Monica L. Skomo, Pharm.D.; Duquesne University, Pittsburgh, PA

228. Implementation of a Diabetes Group Visit Model in a Community-Based, Family Medicine Residency Program.
Dawn C. Fuke, Pharm.D.,1 Michael T. Dotter, Pharm.D.,2 Yelena Rozenfeld, MPH,3 Heather B. Miller, Pharm.D.,3 Cynthia Talbot, M.D.1; (1)Providence Medical Group, Portland, OR; (2)Southern Arizona VA Health Care System, Tucson, AZ; (3)Providence Medical Group – Milwaukee, Milwaukee, OR

229. Reimbursement of a Pharmacist-Run Diabetes and Cardiovascular Risk Reduction Telephonic Program in a Community-Based, Primary Care Medical Group.
Dawn C. Fuke, Pharm.D.,1 John M. Joffer, Pharm.D., Teresa M. Maddalone Swift, Pharm.D., Nanette Bultemeier, Pharm.D., Dara L. Johnson, Pharm.D., Yelena Rozenfeld, MPH; Providence Medical Group, Portland, OR

230. Pneumococcal Vaccination Rates During an Immunization-Focused Ambulatory Care Advanced Pharmacy Practice Experience.
Michelle T. Martin, Pharm.D., Daphne E. Smith-Marsh, Pharm.D., CDE, Jessica B. Michaud, Pharm.D., BCPS, Vicki L. Groo, Pharm.D., Juliana Chan, Pharm.D.; University of Illinois at Chicago, Chicago, IL

Hematology/Anticoagulation

256. Argatroban Usage Patterns in U.S. Hospitals: Results from the Management of Heparin-Induced Thrombocytopenia in U.S. hospitals (the HIT-ME study).
Alan S. Mulitz, M.D.; Nassau University Medical Center, East Meadow, NY

Infectious Diseases
257E. Evaluation of a Revised Treatment Algorithm for Community-Associated Methicillin-Resistant *Staphylococcus aureus* Skin Infections. Marisel Segarra-Newnham, Pharm.D., MPH, FCCP, BCPS; Veterans Affairs Medical Center, West Palm Beach, FL

258. A Retrospective Medication Use Evaluation of Daptomycin in a Medical Center in Taiwan. Yi-Chieh Chen, B.S.,¹ Chin-Hua Kuan, B.S.,¹ Yen-Ying Lee, M.S., Pharm.D.,¹ Hsiang-Yin Chen, M.S., Pharm.D.,¹ Shao-Ling Li, B.S.,² Yu-Ning Aw, B.S.,² Sy-Chyi Ho, B.S.²; (1)Department of Pharmacy, Taipei Medical University-Wan Fang Hospital, Taipei, Taiwan; (2)School of Pharmacy, Taipei Medical University, Taipei, Taiwan

259. Preliminary Evaluation of a Service-Based Inpatient Antimicrobial Stewardship Program at an Academic Medical Center: Surgical Service Implementation. Rachel DiVincenzo, Pharm.D.,¹ Eric W. Mueller, Pharm.D.,² Michelle Wiest, Pharm.D., BCPS, FASHP,² Joseph S. Solomkin, M.D.;¹ (1)College of Pharmacy, University of Cincinnati, Cincinnati, OH; (2)Department of Pharmacy Services, University Hospital and Division of Pharmacy Practice, University of Cincinnati, Cincinnati, OH; (3)University of Cincinnati, College of Medicine, Cincinnati, OH

**Pharmacoeconomics/Outcomes**


273. Utilization Pattern of Intravenous Iron Products at an Academic Medical Center. Elissa V. Klinger, M.S.,¹ Yu-Chen Yeh, M.S.,¹ Adam DeVore, M.D.,² William Churchill, M.S.; Maryann Vienneau, B.S. HA,⁴ Steven Gabardi, Pharm.D.;⁵ (1)Center for Drug Policy, Partners Healthcare, Needham, MA; (2)Department of Medicine, Brigham & Women’s Hospital, Boston, MA; (3)Department of Pharmacy, Brigham & Women’s Hospital, Boston, MA; (4)High Performance Medicine Team 5, Partners Community HealthCare, Inc., Needham, MA; (5)Department of Pharmacy & Renal Division, Brigham & Women’s Hospital; Department of Medicine, Harvard Medical School, Boston, MA

274. A Low-Molecular-Weight Heparin Conversion at 11 Community Hospitals in Connecticut and Massachusetts. Allison V. Tauman, Pharm.D., MPH; VHA, Southport, CT

**RESIDENTS AND FELLOWS RESEARCH IN PROGRESS**

**HIV/AIDS**


**Infectious Diseases**

293. Daptomycin Dose-Effect Relationship Against Vancomycin-Resistant Enterococcal Bacteremia. Truc C. Tran, Pharm.D.,¹ Hannah R. Palmer, Pharm.D., BCPS,¹ Jaye S. Weston, M.S., RPh,¹ Elizabeth B. Hirsch, Pharm.D., Dha N. Shah, Pharm.D., Jessica M. Cottreau, Pharm.D.,² Vincent Tam, Pharm.D.,² Kevin W. Garey, Pharm.D., M.S.;¹ (1)St. Luke’s Episcopal Hospital, Houston, TX; (2)University of Houston-College of Pharmacy, Houston, TX

294. Likelihood of Inadequate Antimicrobial Treatment for Catheter-Related and Primary Bacteremia. Megan Davis, Pharm.D., BCPS,¹ Richard H. Drew, Pharm.D., M.S., BCPS,² Deverick Anderson, M.D., MPH,¹ Michelle Sharpe, Pharm.D.;¹ (1)Duke University Medical Center, Durham, NC; (2)Duke University Medical Center and Campbell University College of Pharmacy and Health Sciences, Durham, NC

**LATE BREAKERS**

**Ambulatory Care**

346. Effect of a Pill Box Clinic on Emergency Department, Hospital Admissions and Urgent Clinic Visits. Nathan D. Culver, Pharm.D., Adraine Lyles, Pharm.D.; Virginia Commonwealth University Health System, Richmond, VA


348E. An Evaluation of the Effectiveness and Safety of Varenicline in a Veteran Population. Samantha M. Wright, Pharm.D.,¹ Molly P. Kurpius, Pharm.D.,² Jacelyn Y. Ng, Pharm.D.;² Donna M. Givone, Pharm.D., BCPP;¹ (1)VA Sierra Pacific Network (VISN 21) Pharmacy Benefits Management Group, Reno, NV; (2)Jesse Brown VA Medical Center, Chicago, IL

**Hematology/Anticoagulation**
352. Impact of Pharmacist-Managed Heparin-Induced Thrombocytopenia Dosing Protocols. 
Sara R. Tebbe, Pharm.D.,¹ Phuong H. Nguyen, Pharm.D.,¹ David R. Putney, Pharm.D.,¹ Lawrence Rice, M.D.²; (¹)The Methodist Hospital, Houston, TX; (²)Methodist Academic Medicine Associates – Weill Cornell Medical College, Houston, TX

Pharmacoeconomics/Outcomes

Jonathan H. Watanabe, Pharm.D., M.S., Ph.D., Candidate, John Ney, M.D.; University of Washington, Seattle, WA

Shivani K. Mhatre, BPharm, Ruchika N. Agrawal, BPharm, Sujit S. Sansgiry, Ph.D.; University of Houston, Houston, TX

Carrie A. Nolan, Pharm.D., Joy L. Meier, Pharm.D.; VA Northern California Health Care System, Martinez, CA

Pharmacoepidemiology

357. Assessment of Seasons as a Factor for Variation of International Normalized Ratio Outside the Therapeutic Range. 
Zenobia J. Dotiwala, BPharm, Edith A. Nutescu, Pharm.D., Daniel R. Touchette, Pharm.D., Bruce L. Lambert, Ph.D.; University of Illinois at Chicago, Chicago, IL

Pharmacokinetics/Pharmacodynamics/Drug Metabolism/Drug Delivery

Karsten R. Duncan, Pharm.D., Richard Pham, Pharm.D., Jannet Carmichael, Pharm.D.; Veterans Health Administration, Reno, NV

360E. Interactions Between Roflumilast and Cytochrome P450 Inducers and Inhibitors: Overview of Existing Studies. 
Gezim Lahu, Ph.D.,¹ Andreas Hün nemeyer, M.D.,¹ Nasr Nassr, M.D.,¹ Nigel McCracken, Ph.D.²; (¹)Department of Pharmacometrics and Pharmacokinetics, Nycomed GmbH, Konstanz, Germany; (²)Department of Exploratory Clinical Sciences, Nycomed GmbH, Konstanz, Germany

Clinical Development, Nycomed GmbH, Konstanz, Germany

361E. Roflumilast in Coadministration with Medications Commonly Prescribed for COPD: An Overview of Existing Studies. 
Gezim Lahu, Ph.D.,¹ Udo-Michael Goehring, M.D.,² Andreas Hün nemeyer, M.D.,¹ Nasr Nassr, M.D.³; (¹)Department of Pharmacometrics and Pharmacokinetics, Nycomed GmbH, Konstanz, Germany; (²)Department of Medical Scientific Strategy/Respiratory, Nycomed GmbH, Konstanz, Germany; (³)Department of Exploratory Clinical Sciences, Nycomed GmbH, Konstanz, Germany